Detalhe da pesquisa
1.
Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis.
Pharmacol Res
; 188: 106668, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36681369
2.
The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression.
Acta Biochim Biophys Sin (Shanghai)
; 55(1): 81-90, 2023 02 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36471952
3.
Long noncoding RNA SNHG17: a novel molecule in human cancers.
Cancer Cell Int
; 22(1): 104, 2022 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35248073
4.
Corrigendum to "Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis" [Pharmacol. Res. 188 (2023) 106668].
Pharmacol Res
; 196: 106922, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37718164
5.
Long noncoding RNA SNHG15: A promising target in human cancers.
Front Oncol
; 13: 1108564, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37056344
6.
HEY1-mediated cisplatin resistance in lung adenocarcinoma via epithelial-mesenchymal transition.
Med Oncol
; 40(1): 18, 2022 Nov 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36396748
7.
Case Report: Long-Term Survival With Anlotinib in a Patient With Advanced Undifferentiated Large-Cell Lung Cancer and Rare Tonsillar Metastasis.
Front Oncol
; 11: 680818, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34249723